Eli Lilly gets FDA EUA status for bamlanivimab to treat Covid-19

Eli Lilly gets FDA EUA status for bamlanivimab to treat Covid-19

Source: 
Pharmaceutical Business Review
snippet: 

Eli Lilly has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its investigational neutralizing antibody bamlanivimab (LY-CoV555) to treat recently diagnosed Covid-19 patients.